Data gathered: April 15
AI Stock Analysis - Recursion Pharmaceuticals (RXRX)
Analysis generated March 19, 2025. Powered by Chat GPT.
Recursion Pharmaceuticals is a biotechnology company focused on discovering and developing therapeutics using advanced computational techniques. The company leverages machine learning and high-throughput experiments to map and navigate human biology. This innovative approach enables Recursion Pharmaceuticals to identify more drug candidates and accelerate drug discovery timelines. With its unique blend of biophysics and advanced data analytics, the company aims to revolutionize the field of drug discovery and development.
Stock Alerts - Recursion Pharmaceuticals (RXRX)
 |
Recursion Pharmaceuticals | April 14 Price is down by -7.3% in the last 24h. |
|
Recursion Pharmaceuticals | April 11 Price is up by 10% in the last 24h. |
|
Recursion Pharmaceuticals | April 10 Price is down by -5.6% in the last 24h. |
|
Recursion Pharmaceuticals | April 9 Price is up by 8.8% in the last 24h. |
Alternative Data for Recursion Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 15 | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 46,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 19 | Sign up | Sign up | Sign up |
| Patents | 35 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 12 | Sign up | Sign up | Sign up |
| Facebook Followers | 697 | Sign up | Sign up | Sign up |
| Reddit Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 730 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 11,398 | Sign up | Sign up | Sign up |
| Twitter Followers | 14,102 | Sign up | Sign up | Sign up |
| Twitter Mentions | 200 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 3,550 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 72 | Sign up | Sign up | Sign up |
| Linkedin Employees | N/A | Sign up | Sign up | Sign up |
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
| Price | $5.51 |
| Target Price | Sign up |
| Volume | 34,390,000 |
| Market Cap | $2.32B |
| Year Range | $3.97 - $10.87 |
| Dividend Yield | 0% |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
 |
Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?April 14 - Yahoo |
|
Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”April 14 - Yahoo |
|
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?April 13 - Yahoo |
 |
Recursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)April 12 - ETF Daily News |
Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week?April 12 - Yahoo Entertainment |
|
|
Alector (NASDAQ:ALEC) vs. Recursion Pharmaceuticals (NASDAQ:RXRX) Financial ReviewApril 11 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 4.5M | 13M | -8.3M | -179M | -165M | -0.530 |
| Q3 '24 | 26M | 12M | 14M | -96M | -88M | -0.340 |
| Q2 '24 | 14M | 13M | 1.3M | -98M | -90M | -0.400 |
| Q1 '24 | 14M | 15M | -770,000 | -91M | -85M | -0.390 |
| Q4 '23 | 11M | 23M | -13M | -93M | -94M | -0.420 |
Insider Transactions View All
| Gibson Christopher filed to sell 1,117,450 shares at $6. March 28 '25 |
| Gibson Christopher filed to sell 1,256,024 shares at $6.4. March 7 '25 |
| Gibson Christopher filed to sell 1,273,156 shares at $8.1. February 7 '25 |
| Gibson Christopher filed to sell 736,633 shares at $7.1. January 13 '25 |
| Gibson Christopher filed to sell 736,633 shares at $7.1. December 6 '24 |
Similar companies
Read more about Recursion Pharmaceuticals (RXRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Recursion Pharmaceuticals?
The Market Cap of Recursion Pharmaceuticals is $2.32B.
What is the current stock price of Recursion Pharmaceuticals?
Currently, the price of one share of Recursion Pharmaceuticals stock is $5.51.
How can I analyze the RXRX stock price chart for investment decisions?
The RXRX stock price chart above provides a comprehensive visual representation of Recursion Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Recursion Pharmaceuticals shares. Our platform offers an up-to-date RXRX stock price chart, along with technical data analysis and alternative data insights.
Does RXRX offer dividends to its shareholders?
As of our latest update, Recursion Pharmaceuticals (RXRX) does not offer dividends to its shareholders. Investors interested in Recursion Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Recursion Pharmaceuticals?
Some of the similar stocks of Recursion Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.